PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptNIH Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Science. Author manuscript; available in PMC Jan 4, 2012.
Published in final edited form as:
PMCID: PMC3251015
NIHMSID: NIHMS339934
Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1α
Shimin Zhao,1,2 Yan Lin,1* Wei Xu,1,2* Wenqing Jiang,1,2* Zhengyu Zha,1 Pu Wang,1,2 Wei Yu,1,2 Zhiqiang Li,4 Lingling Gong,5 Yingjie Peng,6 Jianping Ding,6 Qunying Lei,1,3 Kun-Liang Guan,1,3,7 and Yue Xiong1,2,8
1Molecular and Cell Biology Laboratory, Institute of Biomedical Sciences, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
2School of Life Sciences, Fudan University, 220 Han-Dan Road, Shanghai 200433, China.
3Department of Biological Chemistry, School of Medicine, Fudan University, 130 Dong-An Road, Shanghai 200032, China.
4Department of Neurosurgery, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
5Department of Pathology, Zhongnan Hospital, Wuhan University, Wuhan 430071, China.
6State Key Laboratory of Molecular Biology, Institute of Biochemistry and Cell Biology, Shanghai Institute for Biological Sciences, Chinese Academy of Sciences, 320 Yue-Yang Road, Shanghai 200031, China.
7Department of Pharmacology and Moores Cancer Center, University of California San Diego, La Jolla, CA 92093, USA.
8Department of Biochemistry and Biophysics, Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, NC 27599, USA.
To whom correspondence should be addressed. kuguan/at/ucsd.edu (K.-L.G.); yxiong/at/email.unc.edu (Y.X.)
*These authors contributed equally to this work.
Heterozygous mutations in the gene encoding isocitrate dehydrogenase-1 (IDH1) occur in certain human brain tumors, but their mechanistic role in tumor development is unknown. We have shown that tumor-derived IDH1 mutations impair the enzyme’s affinity for its substrate and dominantly inhibit wild-type IDH1 activity through the formation of catalytically inactive heterodimers. Forced expression of mutant IDH1 in cultured cells reduces formation of the enzyme product,α-ketoglutarate (α-KG), and increases the levels of hypoxia-inducible factor subunit HIF-1α, a transcription factor that facilitates tumor growth when oxygen is low and whose stability is regulated by α-KG. The rise in HIF-1α levels was reversible by an α-KG derivative. HIF-1α levels were higher in human gliomas harboring an IDH1 mutation than in tumors without a mutation. Thus, IDH1 appears to function as a tumor suppressor that, when mutationally inactivated, contributes to tumorigenesis in part through induction of the HIF-1 pathway.
Gliomas are the most common type of human brain tumors and can be classified based on clinical and pathological criteria into four grades. The grade IV glioma, commonly known as glioblastoma multiforme (GBM), has one of the worst prognoses among all types of human tumors and can develop either de novo (primary GBM) or through progression from low-grade tumors (secondary GBM). Although pathologically indistinguishable, primary and secondary GBM exhibit distinct patterns of cancer gene alterations (1). A recent cancer genome sequencing project revealed that the gene encoding IDH1 is somatically mutated predominantly in secondary GBM (2). Three subsequent studies of targeted IDH1 gene sequencing confirmed this finding, together identifying IDH1 mutations in more than 70% of secondary GBM or low-grade gliomas but infrequently in primary GBM (about 5%) (35). Notably, all of the IDH1 mutations identified to date produce a single amino acid substitution at Arg132 (R132) and no obvious inactivating (frame-shift or protein-truncation) mutations were found. This observation, together with the fact that the tumors do not show loss-of-heterozygosity (LOH), has led to speculation that R132 mutations lead to oncogenic activation of the enzyme.
IDH enzymes catalyze the oxidative decar-boxylation of isocitrate (ICT) to produce α-KG. The human genome has five IDH genes coding for three distinct IDH enzymes whose activities are dependent on either nicotinamide adenine dinucleotide phosphate (NADP+-dependent IDH1 and IDH2) or nicotinamide adenine dinucleotide (NAD+-dependent IDH3). Both IDH2 and IDH3 enzymes are localized in the mitochondria and participate in the citric acid (TCA) cycle for energy production, whereas IDH1 is localized in the cytoplasm and peroxisomes (6). The R132 residue is conserved in all NADP+-dependent IDHs.
To explore the functional impact of the tumor-associated mutations at R132, we performed modeling studies based on the previously reported human cytosolic IDH1 crystal structure (7). Among all residues involved in binding with ICT, the side chain of R132 uniquely forms three hydrogen bonds with both the α- and β-carboxyl groups of the substrate ICT, whereas other residues involved in ICT binding form no more than two hydrogen bonds (Fig. 1A). Substitution of R132 with any one of the six amino acids observed in gliomas (His, Ser, Gly, Cys, Val, and Leu) would impair interactions of the enzyme with ICT both sterically and electrostatically. Representative modeling of H132, which corresponds to the most prevalent IDH1 mutation in human gliomas, is shown in Fig. 1A. We determined the in vitro enzymatic activities of three tumor-derived IDH1 mutants, R132H, R132C and R132S, expressed in transformed human embryonic kidney (HEK) 293T cells and found that all three mutants have a greater than 80% reduction in activity as compared with the wild-type (WT) IDH1 (Fig. 1B). Analysis of recombinant IDH1 mutant proteins purified from Escherichia coli likewise displayed little activity in vitro compared with wild-type controls (Fig. 1B). Kinetic analyses of recombinant IDH1 proteins revealed that all three mutant IDH1s had a dramatically reduced affinity for ICT: The Michaelis constants (Kms) of IDH1R132C, IDH1R132S, and IDH1R132H for ICT were increased by factors of 60, 70, and 94, respectively (Fig. 1C). In contrast, the Km for NADP+ and the maximum velocity (Vmax) were not appreciably altered (Fig. 1C). Similarly, mutation of an arginine residue in pig mitochondrial IDH2 equivalent to R132 in human IDH1 caused a dramatic increase in Km for isocitrate (by a factor of 165), with minimal effect on Vmax (8). Because the normal cellular concentration of ICT is 20 to 30 µM (9), which is lower than the Km of the IDH1 mutants, the mutant enzymes are likely to have limited activity under physiological conditions. Together, these structural and biochemical analyses indicate that the tumor-associated IDH1 mutations inactivate the enzyme.
Fig. 1
Fig. 1
Tumor-derived IDH1 mutants have reduced catalytic activity because of impaired isocitrate binding. (A) Structural modeling predicts that mutation of R132 in IDH1 would weaken hydrogen bonding of the enzyme to ICT. Shown is a view of the catalytic active (more ...)
Given that IDH1 normally functions as a homodimer, we hypothesized that the mutant IDH1 molecules in tumor cells form heterodimers with wild-type molecules and, in so doing, dominantly inhibit the activity of wild-type IDH1. To test this hypothesis, we coexpressed His-tagged wild-type and FLAG-tagged R132H mutant IDH1 in E. coli and isolated the heterodimer by sequential affinity purification using first nickel resin and then FLAG beads. Formation of either WT:WT homodimer or WT:R132H heterodimer was confirmed by gel filtration (fig. S1). As expected, the WT:WT homodimers were fully active and the R132H:R132H homodimers were nearly completely inactive (Fig. 2A). Notably, the WT:R132H heterodimer exhibited only 4%of the activity shown by the wild-type enzyme when assayed with limited ICT concentration (Fig. 2A). Normally, IDH1 can adopt at least three distinct conformations during catalysis: a quasi-open conformation when it is in a complex with NADP+, a quasi-closed conformation when it is in a complex with ICT, and a closed conformation when it is in a complex with both NADP+ and ICT (fig. S2A) (7). The two IDH1 subunits act in a cooperative manner and undergo conformational changes in a concerted way. Our modeling study suggests that the impairment in enzyme binding with ICT conferred by the R132 mutation in one subunit might also impair the binding of ICT to the second wild-type subunit. As a result, both subunits would be locked in an unliganded or quasi-open (NADP+-bound) conformation, thereby inhibiting catalytic activity (Fig. 2B for the close-up of the catalytic active site) (fig. S2, B and C). Consistent with this model, we found that the wild-type IDH1 exhibits a sigmoidal curve of cooperative binding to ICT, whereas the WT:R132H heterodimer displayed a hyperbolic curve with a much higher Km (Fig. 2C), indicating that the heterodimer not only loses affinity but also cooperativity toward ICT.
Fig. 2
Fig. 2
The R132H mutation dominantly inhibits IDH1 activity and reduces cellular levels of α-KG. (A) The WT:R132H heterodimer of IDH1 has low specific activity. The specific activities of WT:WT, R132H:R132H, and WT:R132H dimers were measured under conditions (more ...)
We next investigated whether loss of IDH1 activity would alter cellular levels of α-KG, the product of IDH1 catalysis. We used RNA interference to down-regulate endogenous IDH1 and determined the α-KG levels in U-87MG human glioblastoma cells. Two independent short hairpin RNAs (shRNAs) decreased IDH1 mRNA by more than 75% and reduced cellular α-KG levels by up to 50% (fig. S3). Expression of the IDH1R132H mutant at a level similar to the endogenous protein (fig. S4A) in the cytoplasm of U-87MG cells caused a dose-dependent reduction of α-KG levels (Fig. 2D) (fig. S4, A and B). Together, these data indicate that tumor-derived mutant IDH1 dominantly inhibits the wild-type IDH1 by forming a catalytically inactive heterodimer, resulting in a decrease of cellular α-KG.
Because α-KG is required by prolylhydroxylases (PHD), enzymes that hydroxylate and promote the degradation of hypoxia-inducible factor 1α (HIF-1α), we hypothesized that decreased IDH1 activity might stabilize HIF-1α and increase its steady-state levels. We found that HIF-1α protein levels in U-87MG cells were elevated in response to shRNA-mediated knockdown of IDH1 (Fig. 3A). Conversely, overexpression of wild-type IDH1 reduced HIF-1α protein levels in HeLa (fig. S5A) and U-87MG cells (Fig. 3B). Notably, overexpression of IDH1R132H mutant increased HIF-1α protein levels in U-87MG and HEK293T cells (Fig. 3B). These results suggest that IDH1 regulates HIF-1α levels by controlling the level of α-KG. We tested this hypothesis by treating cells with octyl-α-KG, a cell-permeable derivative of α-KG that upon entering the cells is converted into α-KG after hydrolysis of the ester group (10). We found that octyl-α-KG suppressed the HIF-1α induction caused by either IDH1 knockdown in HeLa cells (fig. S5B) or overexpression of IDH1R132H mutant in U-87MG cells (Fig. 3C).We therefore conclude that a reduction in IDH1 activity produces a reduction in α-KG levels that in turn can lead to stabilization of HIF-1α.
Fig. 3
Fig. 3
α-KG mediates the HIF-1α induction in cells with a decreased IDH1 activity (A) IDH1 knockdown elevates HIF-1α levels in U-87MG glioblastoma cells. IDH1 and HIF-1α protein levels were determined by Western blotting from (more ...)
We next determined whether inhibition of IDH1 enzyme activity leads to up-regulated expression of HIF-1α target genes. HIF-1α is a key component of HIF-1, a transcription factor that senses low cellular oxygen levels and that regulates the expression of genes implicated in glucose metabolism, angiogenesis, and other signaling pathways that are critical to tumor growth. Quantitative real-time fluorescence polymerase chain reaction (QPCR) of mRNAs corresponding to three well-established HIF-1α target genes, glucose transporter 1 (Glut1), vascular endothelial growth factor (VEGF), and phosphoglycerate kinase (PGK1) showed that IDH1 knockdown induced the expression of these HIF-1α target genes (fig. S6A). Moreover, expression of the IDH1R132H mutant, but not wild-type IDH1, strongly induced HIF-1α target gene expression (Fig. 4A). Oxalomalate, a competitive inhibitor of IDH1 (11) (fig. S6B), also induced expression of these HIF-1α target genes (Fig. 4B).
Fig. 4
Fig. 4
IDH1 activity affects the levels of HIF-1α and HIF-1α target genes in gliomas and cultured cells. (A) Overexpression of the IDH1R132H mutant in U-87MG cells stimulates expression of HIF-1α target genes (Glut1, VEGF, and PGK1) as (more ...)
Finally, we determined whether IDH1 mutations correlate with elevated levels of HIF-1α in human gliomas. In a collection of 26 glioma samples, we identified 8 tumors that contained the R132H mutation in one allele of IDH1 (table S1) (fig. S7A). Using immunohistochemistry, we compared HIF-1α expression in gliomas with and without IDH1 mutations. We found that 8 tumors harboring the R132H mutation showed a statistically stronger HIF-1α signal than did 12 tumors that did not harbor this mutation (Fig. 4C). In IDH1 mutated tumors, 28.1 ±6.7% of the cells stained positive for HIF-1α, whereas in tumors with wild-type IDH1, only 15.8 ±3.5% of the cells stained positive (P < 0.001) (Fig. 4C). IDH1-mutated gliomas also exhibited an increase in VEGF levels compared with gliomas without IDH1 mutation of similar type and grade (fig. S7B).
In summary, we have shown that IDH1 is likely to function as a tumor suppressor gene rather than as an oncogene. The glioma-associated mutations dominantly inhibit the activity of wild-type IDH1 through heterodimer formation (fig. S8). IDH1 gene mutations in gliomas exhibit two unique features: the lack of LOH and the lack of apparent inactivating mutations such as frame-shift or truncations. Our findings help to explain both features, as dominant inhibition would eliminate the selection pressure to mutate or lose the remaining wild-type allele (LOH) and frame-shift or premature termination would likely generate IDH1 fragments unable to dimerize with and inhibit the wild-type IDH1 protein.
The link between IDH1 and HIF-1α highlights an emerging theme in which mutationally altered metabolic enzymes are thought to contribute to tumor growth by stimulating the HIF-1α pathway and tumor angiogenesis. The genes encoding two TCA enzymes, fumarate hydratase (FH) and succinate dehydrogenase (SDH), have been found to sustain loss-of-function mutations in certain human tumors, which likewise correlate with an increase in HIF-1α levels (10, 11). In addition to affecting PHD, an alteration in α-KG might contribute to tumorigenesis by affecting other dioxygenases that use α-KG as a substrate. IDH1 also catalyzes the production of NADPH; thus, it is possible that a reduction in NADPH levels resulting from IDH1 mutation contributes to tumorigenesis through effects on cell metabolism and growth. Several dozen anticancer agents directly targeting HIF-1α are under development or being tested (12). Our finding that an α-KG derivative can reverse the induction of HIF-1α levels in cultured cells expressing mutant IDH1 suggests that drugs mimicking α-KG may merit exploration as a therapy for gliomas that harbor an IDH1 mutation.
Supplementary Material
Supporting Online Material
Acknowledgments
We thank members of the Fudan Molecular and Cell Biology Laboratory for valuable input; Y. Liu, X. Liu, and H. Zhu for assistance with histology; Z. Bao, L. Yang, Q. Shi, and G. Zhao for clinical samples; and S. Jackson for reading the manuscript. This work is supported by the 985 program from the Chinese Ministry of Education, State Key Development Programs of China (2009CB918401, 2006CB806700), National 863 Program of China (2006AA02A308), China NSF grants (30600112 and 30871255) and Shanghai Key Basic Research Projects (06JC14086, 07PJ14011, and 08JC1400900), and NIH grants (to K.-L.G. and Y.X.). Y. Xiong, K.-L. Guan, and S. Zhao are applying for a patent related to the work on permeable alpha-ketogluterate.
Footnotes
Supporting Online Material
Figs. S1 to S4
Table S1
References
References and Notes
1. Furnari FB, et al. Genes Dev. 2007;21:2683. [PubMed]
2. Parsons DW, et al. Science. 2008;321:1807. [PMC free article] [PubMed]
3. Balss J, et al. Acta Neuropathol. 2008;116:597. [PubMed]
4. Bleeker FE, et al. Hum. Mutat. 2009;30:7. [PubMed]
5. Yan H, et al. N. Engl. J. Med. 2009;360:765. [PMC free article] [PubMed]
6. Winkler BS, DeSantis N, Solomon F. Exp. Eye Res. 1986;43:829. [PubMed]
7. Xu X, et al. J. Biol. Chem. 2004;279:33946. [PubMed]
8. Soundar S, Danek BL, Colman RF. J. Biol. Chem. 2000;275:5606. [PubMed]
9. Albe KR, Butler MH, Wright BE. J. Theor. Biol. 1990;143:163. [PubMed]
10. MacKenzie ED, et al. Mol. Cell. Biol. 2007;27:3282. [PMC free article] [PubMed]
11. Ingebretsen OC. Biochim. Biophys. Acta. 1976;452:302. [PubMed]
12. Semenza GL. Drug Discov. Today. 2007;12:853. [PubMed]